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by the G-BA. Methods: Oncology medicines with completed EBAs by 01 Jan 2015 
were analysed for i) presence of cross-over in pivotal trials; ii) efficacy results before 
and after cross-over and iii) evidence levels granted by the G-BA (proof, indication 
or hint). Results: Cross-over was frequent in oncology, concerning 14 of 28 EBAs 
(50%). For 6 of the 14 medicines, cross-over could be considered ethically required as 
significant differences in overall survival (OS) were demonstrated prior to cross-over. 
For most medicines, data on OS and progression-free survival were reported after 
cross-over (10/14 and 8/14, respectively). Significant differences in OS post-cross-over 
could only be shown for 2 out of the 8 medicines for which no such differences were 
demonstrated before cross-over. An evidence level of proof was granted by the G-BA 
for 3 out of the 14 medicines, all of which were orphan drugs, but none were granted 
for medicines with ethically required cross-over. ConClusions: The G-BA regards 
evidence standards as only partially fulfilled in cases of ethically required cross-over 
in oncology. Highly efficacious drugs with ethically mandated cross-over are there-
fore systematically disadvantaged with regards to the achievable evidence category, 
indicating a bias against innovation. Medicines with a demonstration of superior effi-
cacy and subsequent ethically justified cross-over deserve an evidence level of proof.
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objeCtives: The need and price for cancer drugs will increase while budgets 
are becoming more constrained. Policy makers need to make hard choices about 
which drugs are worthwhile. Inclusion of societal preferences in resource alloca-
tion is emphasized by academic research and policy makers. This study qualita-
tively assesses societal preferences for market access of cancer drugs. Methods: 
Focus group discussions (FGD) with members of the general population in Flanders 
(Belgium) were organized. Participants were recruited through flyers distributed in the 
University Hospitals Leuven and social media. First, the topic of budgetary constraints 
and resource allocation was introduced. Next, introductory statements based on ethi-
cal principles were discussed. Hypothetical scenarios were set up to ask people about 
characteristics of a patient, disease and drug that they would use to prioritize if there 
is only money to use/treat one of them. FGD were led by one researcher, video and 
audio recorded, verbatim transcribed and analyzed using thematic framework analy-
sis. FGD were repeated until data saturation. Participants received a compensation 
of € 20. Results: Three FGD with each six participants were conducted in February 
2015. The median age of participants was 43 years (22-65, N= 18). When participants 
are asked to define criteria they would use to prioritize patients, they mention age and 
life style of a patient and severity of the disease. They prefer to treat the largest patient 
group with the best prognosis. Drugs would be prioritized by participants based on 
the effect on quality of life, side effects and treatment duration. ConClusions: 
Participants would like to maximize the benefits within a restricted budget, but con-
flicts between criteria such as prognosis and severity of disease crop up. Further 
research will quantify the relative importance and the trade-offs between criteria 
that society is willing to make through a discrete choice experiment.
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objeCtives: To understand the impact of supply chain and healthcare system struc-
ture on public price for oncologics in selected emerging markets. Methods: Review 
of published price data and publicly available information from health authorities, 
WHO websites, peer reviewed and scholarly publications. Primary input from current 
payers and healthcare for validation and gap mitigation. Results: In the selected 
countries, when comparing to the US pharmacy price as benchmark, oral targeted 
oncologics were priced lower than injectable oncologics. Brazil and the Mexican pri-
vate sector saw the largest disparity with difference of approximately 40% between 
orals and injectables. Taiwan had the smallest difference between orals and injecta-
bles with only a 4% difference. China had the highest prices among the selected 
countries. In countries with both a public and private market, the prices in the public 
sector were always lower than those in the private sector. The ex-factory prices in 
the selected countries were much closer, with maximum 16% difference between 
lowest to highest price level. Brazil has the highest ex-factory price for orals with 
72% and China has the highest for injectables with 77%. South Korea had the lowest 
ex-factory and pharmacy prices for both orals and injectables. ConClusions: The 
combination of no reimbursement, a regionalized approach to pricing, and a com-
plex distribution chain has led to highest mark-ups at pharmacy level price in China 
among the selected countries despite having similar ex-factory prices. Due to tougher 
price negotiations in the public sectors, targeted oncology products enter the Brazil 
and Mexico markets in the private sector first then enter the public market which 
allows for greater the average price differential between public and private sectors. 
With universal healthcare systems in South Korea and Taiwan and international price 
referencing the price differences between orals and injectables and the mark up from 
ex-factory to pharmacy purchasing price is negligible.
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objeCtives: Three target therapies for advance CRC had been approved by TFDA 
since 2005; only two are under reimbursement now. Long reimbursement process 
had prevented advanced CRC patients from prescribing target therapy. This study 
is to use Cetuximab, the first reimbursed target therapy to evaluate the impact of 
min vs. 23.3 min, -65%). ConClusions: Time savings associated with Dmab SC 
injection were seen for all outcome measures. Opting for Dmab SC injection instead 
of Zol IV infusion should free up the hospital capacity to treat more patients, and 
decrease patients’ treatment burden in Italy.
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objeCtives: The HIRE – Oncology contains clinical oncology data captured as part 
of the Cancer Care Quality Program (CCQP), a novel program by Anthem health 
plans designed to align reimbursement with evidence-based, cost-effective oncol-
ogy treatment, that is integrated with administrative claims data in the HealthCore 
Integrated Research Database (HIRD). This study updates prior research describing 
the baseline characteristics of patients within oncology practices participating in the 
CCQP. Methods: Breast, colon, and lung cancer patients from HIRE-Oncology were 
identified between 6/23/2014 and 3/6/2015 (Intake Period). Patients were character-
ized based on the earliest request to utilize chemotherapy and/or supportive care 
medications (Index Date) during the Intake Period; analyses included patients with ≥ 6 
months of continuous pre-index eligibility. Baseline characteristics were stratified by 
cancer type/stage and included: pathology, biomarkers, health care costs, and Deyo-
Charlson Index (DCI). Results: A total of 2,206 breast, 554 colon, and 796 lung cancer 
patients were identified with mean(SD) ages and DCI’s of 64(10), 56(10), and 61(9) and 
5.6(3.2), 7.6(2.6), and 7.8(2.8), respectively. Stage distributions indicated the greatest 
prevalence with stage IV disease: 36%, 73%, and 74% among breast, colon, and lung 
cancers patients. Pathology results among lung cancer patients demonstrated 78% 
and 22% with non-small cell and small cell cancers, respectively. 36% of breast cancer 
patients were HER2 positive, 34% of lung cancer patients were detected with EGFR 
mutation, and 32% of colon cancer patients were detected with KRAS mutation among 
those reporting test results. Across all stages, total all-cause mean (SD) baseline health 
care costs were $51,430($58,567), $67,760($59,064), and $59,789($55,846) among breast, 
colon, and lung cancer patients, respectively. ConClusions: This updated analysis 
provides valuable initial insight into the demographic and clinical characteristics of 
patients within participating practices during the first year. HIRE-Oncology provides 
a comprehensive picture for commercially-insured oncology patients and baseline 
data for future program evaluation.
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objeCtives: To assess physician support of the 2014 ASCO payment reform pro-
posal, focusing on four components: 1) new patient payments- single payment for 
any new patient until treatment begins; 2) treatment month payments-each month 
the patient is treated; 3) active monitoring month payments-during months when 
the patient is not actively treated but receiving care and support; 4) transition of 
treatment payments-for a change in patient status during a month. Methods: 
Medical-oncologists and hematologist/oncologists across the US, practicing for at 
least 2yrs and managing at least 20 patients, were randomly sampled to participate 
in a cross-sectional survey via a panel. Results: 231 physicians participated (87% 
physicians, 13% medical directors; 67.5% hematologist/oncologists, 32.5% medical-
oncologists). Mean practice duration:15yrs; 53% practice in an academic/community/
Veteran’s facility and 47% in group/solo private practice; geographic distribution: 
South:32%/Northeast:29%/Midwest:23%/West:17%. Only 7% rated the reimburse-
ment climate as “excellent” (good:32%/satisfactory:42%/not very good:20%/bad:2%); 
18% rated the financial status of their cancer program as “excellent” (good:41%/sat-
isfactory:33%/not very good:7%/bad:< 1%). Physicians reporting that they “strongly” 
or “somewhat” support the components of the 2014 ASCO proposal: 1) new patient 
payments:47%; 2) treatment month payments:57%; 3) active monitoring month pay-
ments:55%; and 4) transition of treatment payments:54%. Physician rating of “strong/
somewhat support” based on perception of reimbursement climate (excellent/good 
vs. satisfactory/not very good/bad): 1) new patient payments:55%/42%; 2) treatment 
month payments:66%/51%; 3) active monitoring month payments:65%/48%; 4) 
transition of treatment payments:61%/50%. “Strong/somewhat” support based on 
perception of financial status of their cancer program (excellent/good vs. satisfac-
tory/not very good/bad): 1) new patient payments:49%/44%; 2) treatment month 
payments:61%/52%; 3) active monitoring month payments:60%/47%; 4) transition of 
treatment payments:59%/47%. ConClusions: About half of the physicians in the 
study supported the components of ASCO’s 2014 proposed payment reform, espe-
cially if they already considered the current reimbursement climate and financial 
status of the cancer program to be positive.
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objeCtives: In Germany, an early benefit assessment (EBA) by the Federal Joint 
Committee (G-BA) is compulsory for all new drugs. Pre-defined treatment switching, 
often called ‘cross-over’, is often seen in oncology clinical trials. Cross-over is usu-
ally implemented for ethical reasons, i.e. to ensure access to a beneficial treatment 
for all patients, but may confound data analysis by improving efficacy in the con-
trol arms. We aimed to analyse the impact of cross-over on evidence levels granted 
